# Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1

> **NCT00678886** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 272 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** otelixizumab infusion plus physician determined standard of care
- **BIOLOGICAL:** placebo infusion plus physician determined standard of care

## Key facts

- **NCT ID:** NCT00678886
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-29
- **Primary completion:** 2012-01-31
- **Final completion:** 2012-01-31
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2017-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678886, "Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00678886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*